

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3051968

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ATYR PHARMA, INC.	01/30/2012
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	PANGU BIOPHARMA LIMITED
<b>Street Address:</b>	18/F, EDINBURGH TOWER, THE LANDMARK
<b>Internal Address:</b>	15 QUEEN'S ROAD CENTRAL
<b>City:</b>	HONG KONG
<b>State/Country:</b>	HONG KONG
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14262272
<b>Patent Number:</b>	8753638
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2064528700
<b>Email:</b>	WTHOMAS@COOLEY.COM
<b>Correspondent Name:</b>	COOLEY LLP
<b>Address Line 1:</b>	1299 PENNSYLVANIA AVENUE, NW SUITE 700
<b>Address Line 2:</b>	ATTN: PATENT DEPARTMENT/MARK ROGEL
<b>Address Line 4:</b>	WASHINGTON, D.C. 20004
<b>ATTORNEY DOCKET NUMBER:</b>	ATYR-015_3
<b>NAME OF SUBMITTER:</b>	MARK E. ROGEL
<b>SIGNATURE:</b>	/Mark E. Rogel/
<b>DATE SIGNED:</b>	10/03/2014
<b>Total Attachments: 2</b>	
source=ATYR-015_ASSIGN_ATYR-PANGU_3#page1.tif	
source=ATYR-015_ASSIGN_ATYR-PANGU_3#page2.tif	

## ASSIGNMENT

WHEREAS, aTYR Pharma, Inc. (hereinafter referred to as "aTYR"), a corporation of the State of Delaware having a place of business at 3565 General Atomics Court, Suite 103, San Diego, California 92121, has rights in the following patent applications and the invention(s) disclosed therein:

Application No.	Title	Filing Date
U.S. 61/160,630	COMPOSITIONS AND METHODS COMPRISING HISTIDYL-IRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES	March 16, 2009
U.S. 61/239,747	COMPOSITIONS AND METHODS COMPRISING HISTIDYL-IRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES	September 3, 2009
U.S. 12/725,272	COMPOSITIONS AND METHODS COMPRISING HISTIDYL-IRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES	March 16, 2010
PCT/US2010/027525	COMPOSITIONS AND METHODS COMPRISING HISTIDYL-IRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES	March 16, 2010

WHEREAS, Pangu BioPharma Limited (hereinafter referred to as "Pangu"), having a place of business at 18/F, Edinburgh Tower, The Landmark, 15 Queen's Road Central, Hong Kong, Special Administrative Region of the People's Republic of China, is desirous of acquiring a 50% undivided right, title and interest in and to aTYR's rights in said patent applications and invention(s) disclosed therein, and in and to any letters patent(s) that claim the priority benefit of said patent applications in the United States and in any and all foreign countries;

NOW, THEREFORE, for valuable consideration, the receipt of which is hereby acknowledged, aTYR hereby sells, assigns and transfers unto Pangu, a 50% undivided right, title and interest in and to aTYR's rights in said patent applications and invention(s) disclosed therein, and in and to any and all letters patent(s) which claim priority to said patent applications and any and all letters patent(s) which claim the invention(s) disclosed therein and which may be granted in the United States of America and its territorial possessions, including any extensions or adjustments in term thereof and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications jointly in the name of aTYR and Pangu and to claim priority rights deriving from said

United States patent applications to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention(s), patent applications and all letters patent(s) on said invention(s) or claiming priority to said patent applications to be held and enjoyed by Pangu and its successors and assigns for their use and benefit. aTYR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue jointly all letters patent on said invention(s) to aTYR and Pangu. aTYR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention(s), for litigation regarding said letters patent, or for the purpose of protecting title to said invention(s) or letters patent therefor.

1/30/2012  
Date

[Signature]  
Name: John D. Mendlein  
Title: CEO and Executive Chairman of aTYR Pharma, Inc.

I certify that I know or have satisfactory evidence that John D. Mendlein is the person who appeared before me, and said person acknowledged that he signed this instrument, on oath stated that he was authorized to execute the instrument, and acknowledged it as Chief Executive Officer and Executive Chairman of aTYR Pharma, Inc., to be the free and voluntary act of said corporation(s) for the uses and purposes mentioned in the instrument.

Date 1/30/2012  
(Type or Print)

Signed at 3515 General Atomics Ct  
San Diego CA 92121

Bonnie Alexander  
(Type or Print Name of Witness)

Bonnie Alexander  
(Signature of Witness)